Chimerix: This Misunderstood Biotech, Trading Near Cash, Offers Substantial Upside – Seeking Alpha
Seeking Alpha |
Chimerix: This Misunderstood Biotech, Trading Near Cash, Offers Substantial Upside
Seeking Alpha Brincidofovir has shown in vitro efficacy against all of the families of DNA viruses that affect humans – cytomegalovirus (CMV), adenovirus, BK virus, and herpes simplex viruses. Brincidofovir should be approved as the first antiviral smallpox … and more » |
Rare Diseases: Biotech’s High Risk, Highest Reward Sub-Sector – Forbes
Forbes |
Rare Diseases: Biotech's High Risk, Highest Reward Sub-Sector
Forbes In How To Maximize Biotech Returns Under Donald Trump, Todd Hagopian highlighted Rare Diseases, a sub-sector that includes companies developing novel drugs for diseases that affect small patient populations. The often incredibly high price tags for ... |